ADPT (Adaptive Biotechnologies Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ADPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-18 | FRANCIS LO | Chief People Officer | MIXED | — | — |
| 2026-09-17 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-09-02 | KATEY EINTERZ OWEN | Director | G | — | — |
| 2026-08-28 | KATEY EINTERZ OWEN | Director | Sell | — | — |
| 2026-08-20 | ROBERT HERSHBERG | Director | MIXED | — | — |
| 2026-08-19 | PETER M NEUPERT | Director | MIXED | — | — |
| 2026-08-19 | CHAD M ROBINS | CEO and Chairman | MIXED | — | — |
| 2026-08-12 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-08-03 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-07-23 | HARLAN S ROBINS | Chief Scientific Officer | MIXED | — | — |
| 2026-07-20 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-07-17 | FRANCIS LO | Chief People Officer | MIXED | — | — |
| 2026-07-07 | HARLAN S ROBINS | Chief Scientific Officer | Sell | — | — |
| 2026-07-06 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-07-06 | FRANCIS LO | Chief People Officer | MIXED | — | — |
| 2026-06-29 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-06-29 | MICHELLE RENEE GRIFFIN | Director | MIXED | — | — |
| 2026-06-17 | HARLAN S ROBINS | Chief Scientific Officer | Sell | — | — |
| 2026-06-15 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-06-08 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-06-08 | FRANCIS LO | Chief People Officer | MIXED | — | — |
| 2026-05-20 | KYLE PISKEL | Chief Financial Officer | Sell | — | — |
| 2026-04-29 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-24 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-21 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-16 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-13 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-10 | FRANCIS LO | Chief People Officer | MIXED | — | — |
| 2026-04-10 | HARLAN S ROBINS | Chief Scientific Officer | Sell | — | — |
| 2026-04-08 | CHAD M ROBINS | CEO and Chairman | Sell | — | — |
| 2026-04-08 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-04-02 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-26 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-23 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-18 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-13 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | Sell | — | — |
| 2026-03-13 | FRANCIS LO | Chief People Officer | Sell | — | — |
| 2026-03-13 | MICHELLE RENEE GRIFFIN | Director | Sell | — | — |
| 2026-03-13 | KYLE PISKEL | Chief Financial Officer | Sell | — | — |
| 2026-03-13 | SHARON BENZENO | Chief Commercial Ofc Imm Med | Sell | — | — |
| 2026-03-13 | HARLAN S ROBINS | Chief Scientific Officer | Sell | — | — |
| 2026-03-13 | CHAD M ROBINS | CEO and Chairman | Sell | — | — |
| 2026-03-13 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-10 | JULIE RUBINSTEIN | President and COO | MIXED | — | — |
| 2026-03-09 | FRANCIS LO | Chief People Officer | Sell | — | — |
| 2026-03-06 | PETER M NEUPERT | Director | A | — | — |
| 2026-03-06 | JULIE RUBINSTEIN | President and COO | A | — | — |
| 2026-03-06 | ROBERT HERSHBERG | Director | A | — | — |
| 2026-03-06 | SUSAN BOBULSKY | Chief Commercial Officer, MRD | A | — | — |
| 2026-03-06 | KATEY EINTERZ OWEN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 38,406,607 | — |
| — | 10%+ Owner | 36,108,295 | — |
| — | 10%+ Owner | 33,493,708 | — |
| — | 10%+ Owner | 33,493,708 | — |
| — | 10%+ Owner | 30,993,708 | — |
| — | 10%+ Owner | 29,993,708 | — |
| — | Director | 13,116,594 | — |
| — | Director | 12,702,505 | — |
| — | Director | 3,966,016 | — |
| — | CEO and Chairman | 2,683,043 | — |
| — | Chief Scientific Officer | 1,312,058 | — |
| — | Chief Financial Officer | 547,009 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ADPT quote page; the site-wide leaderboard is on the insider transactions hub.